Management of Children with Psoriasis During the COVID-19 Pandemic
Nikolay N. Murashkin,
Alexander I. Materikin,
Eduard T. Ambarchian,
Roman V. Epishev,
Leonid A. Opryatin,
Roman A. Ivanov https://doi.org/10.15690/vsp.v20i5.2321
Abstract
The spread of new coronavirus infection (COVID-19) changes specialists' approaches to patients with chronic diseases, including those with chronic dermatoses. The high risk of COVID-19 complications in patients with psoriasis is connected to the features of disease pathogenesis (such as high activity of proinflammatory cytokines) and used immunosuppressive therapy. Psoriasis affects up to 1% of children in Europe, while 10-20% of them have moderate or severe form of disease. These children may require immunosuppressive treatment, including genetically engineered biological therapy. There is only limited data on adults and children with psoriasis during the COVID-19 pandemic.
Supporting agencies: The article has been funded by Pfizer.
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children's Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical Academy
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Nikolay N. Murashkin —receiving research grants from pharmaceutical companies Janssen, Eli Lilly, Pfizer, Celgene, AbbVie, Scientific consultant of Galderma, Pierre Fabre, Bayer, Astellas, Libriderm.
Alexander I. Materikin
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Alexander I. Materikin —receiving research grants from pharmaceutical companies Janssen, Eli Lilly, Pfizer, Celgene, AbbVie. Scientific consultant of Bioderma, Libriderm.
Eduard T. Ambarchian
Research Institute of Pediatrics and Children's Health in “Central Clinical Hospital of the Russian Academy of Sciences”
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Eduard T. Ambarchyan — receiving research grants from pharmaceutical companies Janssen, Eli Lilly, Pfizer, Celgene, AbbVie. Scientific consultant of Bioderma, Libriderm.
Roman V. Epishev
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Roman V. Epishev — receiving research grants from pharmaceutical companies Janssen, Eli Lilly, Pfizer, Celgene, AbbVie. Scientific consultant of Bioderma, Libriderm.
Leonid A. Opryatin
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
No conflict of interests.
Roman A. Ivanov
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
No conflict of interests.
References
1. Munster VJ, Koopmans M, van Doremalen N. A novel coronavirus emerging in China — Key questions for impact assessment. N Engl J Med. 2020;382(8):692-694. doi: 10.1056/NEJMp2000929
2. Stopkoronavirus. rf. (In Russ). Доступно по: https://xn--80aesfpebagmfblc0a.xn--p1ai/information. Ссылка активна на 26.10.2021.
3. World Health Organization. Protect yourself and others from the spread COVID-19. 2020. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. Accessed on October 26, 2021.
4. Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3
5. Gisondi P, Facheris P, Dapavo P. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373-374. doi: 10.1111/bjd.19158
6. Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031
7. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. doi: 10.1038/jid.2012.339
8. Menter A, Cordoro KM, Davis DMR. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049
9. Mahil SK, Dand N, Mason KJ et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2020;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007
10. Bardazzi F, Loi C, Sacchelli L, Di Altobrando A. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat. 2020;31(4):320-321. doi: 10.1080/09546634.2020.1749545
11. Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the northern Italy experience. Br J Dermatol. 2020;183(2):373-374. doi: 10.1111/bjd.19158
12. Carugno A, Gambini DM, Raponi F, et al. COVID-19 and biologics for psoriasis: a high-epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol. 2020;83(1):292-294. doi: 10.1016/j.jaad.2020.04.165
13. Megna M, Ruggiero A, Marasca C, Fabbrocini G. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328-329. doi: 10.1080/09546634.2020.1757605
14. Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J Dermatolog Treat. 2020;1-5. doi: 10.1080/09546634.2020.1789051
15. Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475. doi: 10.1111/dth.13475
16. Polat AK, Topal IO, Karadag AS, et al. The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691. doi: 10.1111/dth.14691
17. COVID-19 Situation report, Turkey. 2020. Available online: https://covid19.saglik.gov.tr/Eklenti/37743/0/covid-19-situation-report-v4pdf.pdf. Accessed on October 27, 2021.
18. Beytout Q, Pepiot J, Maruani A, et al. Impact of the COVID-19 pandemic on children with psoriasis. Ann Dermatol Venereol. 2021;148(2):106-111. doi: 10.1016/j.annder.2021.01.005
19. Ciuca I.M. COVID-19 in children: an ample review. Risk Manag Healthc Policy. 2020;13:661-669. doi: 10.2147/RMHP.S257180
20. PsoProtect. Summary data from PsoProtect's first 200 cases. Available online: https://psoprotect.org/current-data. Accessed on October 27, 2021.
21. Mahe E, Maccari F, Ruer-Mulard M, et al. Psoriasis de l'enfant vu en milieu liberal: les aspects cliniques et epidemiologiques different des donnees habituellement publiees. Ann Dermatol Venereol. 2019;146:354-362. doi: 10.1016/j.annder.2019.01.024
22. Skayem C, Cassius C, Ben Kahla M, et al. Teledermatology for COVID-19 cutaneous lesions: substitute or supplement? J Eur Acad Dermatol Venereol. 2020;34(10):e532-e533. doi: 10.1111/jdv.16630
23. Onsun N, Gunej B, Yabaci A. Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center. Dermatol Ther. 2021;34(1):e14623. doi: 10.1111/dth.14623
24. Haberman R, Axelrad J, Chen A, Castillo R, et al. Covid-19 in immune-mediated inflammatory diseases-case series from New York. N Engl J Med. 2020;383(1):85-88. doi: 10.1056/NEJMc2009567
25. Conti A, Lasagni C, Bigi L, Pellacani G. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs. J Eur Acad Dermatol Venereol. 2020;34(8):e360-e361. doi: 10.1111/jdv.16587
26. Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and metaanalysis. Expert Opin Drug Saf. 2016;15(sup1):11-34. doi: 10.1080/14740338.2016.1240783
27. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8
28. Del Valle DM, Kim-Schulze S, Huang H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9
29. Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol. 2020;5(49):eabd1554. doi: 10.1126/sciimmunol.abd1554
30. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163(3):1521-1528.
31. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681-1690. doi: 10.1002/art.1780361206
32. Ingegnoli F, Fantini F, Favalli E, et al. Inflammatory and pro-thrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175-179. doi: 10.1016/j.jaut.2008.07.002
33. Antunes Brito C, Paiva JG, Pimentel FP, et al. COVID-19 in patients with rheumatological diseases treated with anti-TNF. Ann Rheum Dis. 2021;80(5):e62. doi: 10.1136/annrheumdis-2020-218171
34. Yousaf A, Gayam S, Feldman S, et al. Clinical outcomes of CoVid-19 in patients taking tumor necrosis factor inhibitors and/ or methotrexate: a multi-center research network study. J Am Acad Dermatol. 2020;84(1):70-75. doi: 10.1016/j.jaad.2020.09.009
Review
For citations:
Murashkin N.N., Materikin A.I., Ambarchian E.T., Epishev R.V., Opryatin L.A., Ivanov R.A. Management of Children with Psoriasis During the COVID-19 Pandemic. Current Pediatrics. 2021;20(5):441-445. (In Russ.) https://doi.org/10.15690/vsp.v20i5.2321
Views:
474
Email this article 
